Redeye provides a short research update following Alzinova’s recent rights issue of approximately SEK35.7m and positive phase Ib final results. While securing financing through a partnership would have been the preferred outcome, we view this capital raise as a necessary step to extend the company’s financial runway, carry out preparations ahead of the phase II study and enhance its negotiating position in ongoing partnership discussions.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/